Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.−). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.−). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

A composition and method for use in a dental treatment, such as root canal. The composition eliminates the need for uncomfortable and time-consuming needle injections before application of prep composition. The composition is a mixture of a lubricant, a disinfecting agent, a chelating agent and an anesthetic, preferably articaine, and may also include epinephrine. A method for preparing an area of the patient's mouth for the dental treatment, such as a root canal, is achieved by preparing the disclosed composition and administering it to the area of the patient's mouth to be treated. The composition provides simultaneous antibacterial action and numbing action with a one-step application.

A composition and method for use in a dental treatment, such as root canal. The composition eliminates the need for uncomfortable and time-consuming needle injections before application of prep composition. The composition is a mixture of a lubricant, a disinfecting agent, a chelating agent and an anesthetic, preferably articaine, and may also include epinephrine. A method for preparing an area of the patient's mouth for the dental treatment, such as a root canal, is achieved by preparing the disclosed composition and administering it to the area of the patient's mouth to be treated. The composition provides simultaneous antibacterial action and numbing action with a one-step application.

The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.

The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Provided herein, inter alia, are methods and compositions including thiol-containing compounds for treating coronavirus infection.